Side-by-side comparison of AI visibility scores, market position, and capabilities
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Cambridge/Colorado trapped-ion quantum computing (Honeywell majority; $625M+/$5B valuation Jun 2024); Helios Nov 2025 at 98 physical/48 logical qubits with 99.9975% fidelity serving Amgen/BMW/JPMorgan competing with IBM Quantum.
Quantinuum is a Cambridge, UK and Broomfield, Colorado-based integrated quantum computing company — majority owned by Honeywell (NASDAQ: HON) with $625+ million in total funding including a $300 million round led by JPMorgan Chase at a $5 billion valuation in June 2024 — operating the world's most accurate commercial quantum computers using trapped-ion technology combined with quantum software from Cambridge Quantum. In November 2025, Quantinuum launched Helios, its third-generation quantum computer featuring 98 physical qubits and 48 logical error-corrected qubits with 99.9975% single-qubit gate fidelity and 99.921% two-qubit gate fidelity — the highest-accuracy general-purpose commercial quantum computer commercially available. Serving enterprise customers including Amgen (drug discovery), BMW Group (materials simulation), JPMorgan Chase (financial optimization), and SoftBank Corp. (AI acceleration), Quantinuum was formed in November 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum Computing. CEO Ilyas Khan.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.